vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 32.1%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 10.6%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CLMB vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $168.4M |
| Net Profit | $3.3M | — |
| Gross Margin | 14.5% | — |
| Operating Margin | 2.1% | 50.6% |
| Net Margin | 1.8% | — |
| Revenue YoY | 32.1% | 143.7% |
| Net Profit YoY | -9.5% | — |
| EPS (diluted) | $0.18 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $168.4M | ||
| Q3 25 | $161.3M | $87.3M | ||
| Q2 25 | $159.3M | $82.4M | ||
| Q1 25 | $138.0M | $65.0M | ||
| Q4 24 | $161.8M | $69.1M | ||
| Q3 24 | $119.3M | $51.6M | ||
| Q2 24 | $92.1M | $73.8M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $4.7M | $-31.3M | ||
| Q2 25 | $6.0M | $-12.7M | ||
| Q1 25 | $3.7M | $-40.5M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $5.5M | $-29.5M | ||
| Q2 24 | $3.4M | $-61.9M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 20.2% | — |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 50.6% | ||
| Q3 25 | 4.3% | -11.4% | ||
| Q2 25 | 5.0% | 8.6% | ||
| Q1 25 | 3.5% | -34.0% | ||
| Q4 24 | 7.2% | -6.4% | ||
| Q3 24 | 7.1% | -31.0% | ||
| Q2 24 | 4.6% | 3.5% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.9% | -35.9% | ||
| Q2 25 | 3.7% | -15.4% | ||
| Q1 25 | 2.7% | -62.2% | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.6% | -57.2% | ||
| Q2 24 | 3.7% | -83.9% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.32 | ||
| Q3 25 | $1.02 | $-0.16 | ||
| Q2 25 | $1.30 | $-0.06 | ||
| Q1 25 | $0.81 | $-0.21 | ||
| Q4 24 | $1.52 | $-0.14 | ||
| Q3 24 | $1.19 | $-0.15 | ||
| Q2 24 | $0.75 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $-302.0M |
| Total Assets | $458.8M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $167.9M | ||
| Q3 25 | $49.8M | $92.4M | ||
| Q2 25 | $28.6M | $86.1M | ||
| Q1 25 | $32.5M | $114.6M | ||
| Q4 24 | $29.8M | $144.8M | ||
| Q3 24 | $22.1M | $144.7M | ||
| Q2 24 | $48.4M | $189.3M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $-302.0M | ||
| Q3 25 | $109.3M | $-451.4M | ||
| Q2 25 | $105.2M | $-433.5M | ||
| Q1 25 | $95.6M | $-426.2M | ||
| Q4 24 | $90.6M | $-388.7M | ||
| Q3 24 | $87.7M | $-370.2M | ||
| Q2 24 | $79.8M | $-344.2M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $465.9M | ||
| Q3 25 | $376.1M | $364.0M | ||
| Q2 25 | $420.7M | $347.1M | ||
| Q1 25 | $370.1M | $324.0M | ||
| Q4 24 | $469.2M | $343.8M | ||
| Q3 24 | $371.9M | $314.1M | ||
| Q2 24 | $302.8M | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $45.2M | ||
| Q3 25 | $22.2M | $-4.3M | ||
| Q2 25 | $-2.2M | $-31.4M | ||
| Q1 25 | $8.5M | $-22.6M | ||
| Q4 24 | $16.0M | $-35.0M | ||
| Q3 24 | $-3.6M | $-35.3M | ||
| Q2 24 | $7.3M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
